fbpx
June 6, 2022

Targeted Therapy an ‘Important Advance’ in Childhood Glioma Targeted Therapy an ‘Important Advance’ in Childhood Glioma

CHICAGO —Targeted therapy achieved significantly higher responses rates and longer progression-free survival (PFS) when compared with standard chemotherapy in pediatric patients with BRAF V600-mutant low-grade gliomas, […]
June 6, 2022

Obesity in Adolescence Raises Risk for Adult Type 1 Diabetes Obesity in Adolescence Raises Risk for Adult Type 1 Diabetes

Obesity in adolescence is linked to an increased risk for type 1 diabetes onset in adulthood, new research suggests. These new data, from Israeli military recruits […]
June 6, 2022

Methotrexate’s First Evidence of Disease Modification in Pre-RA Methotrexate’s First Evidence of Disease Modification in Pre-RA

COPENHAGEN — Temporary methotrexate in clinically suspected arthralgia delays but does not prevent clinical arthritis development; however, it does lead to sustained reduction of disease burden and […]
June 6, 2022

Crohn’s Disease Biomarker Appears Years Ahead of Diagnosis Crohn’s Disease Biomarker Appears Years Ahead of Diagnosis

Anti–granulocyte-macrophage colony-stimulating factor (GM-CSF) autoantibodies predict complicated Crohn’s disease (CD) years before signs or symptoms of the disease appear, according to new data. A study of […]
June 6, 2022

‘Remission Is Possible’ for Patients With Type 2 Diabetes ‘Remission Is Possible’ for Patients With Type 2 Diabetes

A novel approach that involves sensors, artificial intelligence, and real-time individualized lifestyle guidance from an app and live coaches led to a high rate of remission […]
June 6, 2022

FDA Advisers Consider Novavax COVID-19 Vaccine This Week FDA Advisers Consider Novavax COVID-19 Vaccine This Week

The FDA’s vaccine advisors are scheduled to meet on Tuesday to consider authorizing the Novavax COVID-19 vaccine. The committee will vote on whether the benefits of […]
June 6, 2022

Enhertu Benefit in HER2-Low Breast Cancer: ‘Practice Changing’ Enhertu Benefit in HER2-Low Breast Cancer: ‘Practice Changing’

CHICAGO — Breast cancer patients with low levels of HER2 expression, previously considered untreatable with HER2-targeted therapies, benefited from the anti-HER2 antibody drug conjugate trastuzumab deruxtecan. The therapy […]
June 6, 2022

Teclistamab Shows ‘Promising’ Activity in R/R Multiple Myeloma Teclistamab Shows ‘Promising’ Activity in R/R Multiple Myeloma

A weekly subcutaneous dose of teclistamab resulted in high response rates among adults with relapsed or refractory multiple myeloma, based on data from 165 patients in […]
June 6, 2022

Physicians React: Burnout Rates Are Alarming, so Who Should Drive Change? Physicians React: Burnout Rates Are Alarming, so Who Should Drive Change?

When physicians lament they feel burned out at work, what exactly do they mean? Here’s how one doctor describes conditions that lead to burnout: “I barely […]
Prev page
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548549550551552553554555556557558559560561562563564565566567568569570571572573574575576577578579580581582583584585586587588589590591592593594595596597598599600601602603604605606607608609610611612613614615616617618619620621622623624625626627628629630631632633634635636637638639640641642643644645646647648649650651652653654655656657658659660661662663664665666667668669670671672673674675676677678679680681682683684685686687688689690691692693694695696697698699700701702703704705706707708709710711712713714715716717718719720721722723724725726727728729730731732733734735736737738739740741742743744745746747748749750751752753754755756757758759760761762763764765766767768769770771772773774775776777778779780781782783784785786787788789790791792793794795796797798799800801802803804
Next page
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0